CTT Pharmaceutical Holdings, Inc., listed as the reporting person with the title CEO, reported a direct purchase of 2,000 CTTH shares at $0.0570 per share on October 15, 2026. The reported direct holdings after the purchase were 9,436,656 shares, and no Rule 10b5-1 plan is reported.
CTT Pharmaceutical Holdings, Inc. says it is submitting a response letter from the auditor associated with its prior Form 8-K. The auditor agrees with what the company previously filed.
CTT Pharmaceutical Holdings, Inc. (CTTH) disclosed that its relationship with its auditor has ended. The company stated there were no disagreements over accounting practices and said the auditor is no longer handling SEC reporting companies. CTT said it will begin looking for a new auditor and contact another auditor it has worked with before.
CTT Pharmaceutical Holdings, Inc. reported a direct purchase of 3,700 shares at $0.0550 per share on October 6, 2026. The reporting person is identified as CEO and director and reported 9,433,656 directly held shares after the purchase. No Rule 10b5-1 plan is reported.
CTT Pharmaceutical Holdings, Inc., identified as the reporting person with the title CEO, reported a direct purchase of 10,100 shares on September 22, 2026, at $0.045 per share. The amendment corrects the post-transaction holding to 9,424,556 shares. No Rule 10b5-1 plan is reported.
CTT Pharmaceutical Holdings, Inc. (CTTH) reported a direct purchase by its CEO of 3,400 shares at $0.055 per share on September 28, 2026. The reported direct holdings after the purchase were 9,429,956 shares. No Rule 10b5-1 plan is reported.
CTT Pharmaceutical Holdings, Inc. (CTTH) added Karen Larson as an independent board member. The announcement identifies her as a Certified Financial Planner (CFP) and says she has experience running companies.
Her background includes creating an analytical reporting business that was sold to Morningstar and serving as a Senior Vice President, Investment Banker at Chase Manhattan Bank. She has been a founder of Broad Avenue Studios, Inc. since 2017.
CTT Pharmaceutical Holdings, Inc. (CTTH) reported that its CEO, as a director and officer of the company, purchased 10,100 shares of CTTH on September 22, 2026 in an open market or private transaction at $0.045 per share. Following this transaction, the reporting person directly holds 1,056,800 shares of CTTH common stock. No Rule 10b5-1 trading plan is indicated.
CTT Pharmaceutical Holdings, Inc. (CTTH) reported another pre-revenue quarter for the six months ended June 30, 2026, with a net loss of $99,908 compared with $90,273 a year earlier. Total assets were $67,434, almost entirely intangible assets of patents and trademarks of $67,403, while cash was only $31 at June 30, 2026.
Current liabilities were $41,391, including related-party payables of $21,949 and a related-party note payable of $19,442, resulting in low stockholders’ equity of $26,043. The company disclosed no revenue-producing activities and its auditors and management cited substantial doubt about its ability to continue as a going concern. Management highlights a global patent portfolio, recent U.S. approval of a CIP application for a nicotine strip and a preliminary LOI in Europe, and plans to deploy about $500,000 of prospective financing to establish manufacturing, though such financing is not assured.
CTT Pharmaceutical Holdings, Inc. (CTTH) reports that its reporting person, identified as a director and CEO of the company, purchased 10,900 shares of CTTH common stock on September 16, 2026 at $0.048 per share, bringing the reported direct holdings to 9,414,456 shares. No Rule 10b5-1 trading plan is indicated.